Precision – temporal

BostonGene to Showcase Transformative Impact of AI-Driven Profiling with Six Abstracts at the 67th American Society of Hematology Annual Meeting & Exposition

2 weeks ago talkbio0Tagged 67th, AI-driven, annual, Asymmetric Septal Hypertrophy, Biological Markers, BostonGene, Clinical Trials, Hematology (discipline), immune profiling, meeting, Molecular Profiling, Multiple Myeloma, Neoplasms, Precision - temporal, Stratification

BostonGene; AI-driven molecular profiling; hematology; 67th ASH Annual Meeting; immune profiling; multiple myeloma; patient stratification; clinical trials; biomarkers; precision oncology

Ratio Therapeutics Appoints Marcel Reichen as Chief Strategy Officer

1 month ago talkbio0Tagged Cancer Therapeutic Procedure, Chief Strategy Officer, Drug Industry, Marcel Reichen, Neoplasms, Precision - temporal, radioligand therapy, Radiopharmaceuticals, Ratio Therapeutics, Strategic Growth

Ratio Therapeutics; Marcel Reichen; Chief Strategy Officer; radiopharmaceuticals; oncology; radioligand therapy; pharmaceutical industry; cancer treatment; strategic growth; precision oncology

Odyssey Therapeutics Secures $213M Series D to Accelerate Autoimmune Clinical Portfolio

3 months ago talkbio0Tagged Autoimmune Diseases, clinical pipeline, Immunoregulation, Inhibitor, investors, Odyssey, Precision - temporal, preclinical programs, Protac, RIPK2, Series D financing, Technology

Odyssey Therapeutics; Series D financing; $213 million; autoimmune diseases; clinical pipeline; preclinical programs; precision immunomodulation; RIPK2 inhibitor; PROTAC technology; investors

Exclusive: Merida Biosciences gets $121M to treat autoimmune and allergy diseases at their roots

8 months ago talkbio0Tagged Autoimmune, Autoimmune Diseases, Precision - temporal

Autoimmune, Autoimmune Diseases, Precision – temporal

GE HealthCare and UCSF Collaborate on Innovative Imaging Solutions for Cancer and Neurodegenerative Diseases

11 months ago talkbio0Tagged brain health, Cancer Imaging, ELAVL2 gene, GE HealthCare, innovation, Joint Research Program, Neoplasms, Neurodegenerative Disease Imaging, Precision - temporal, UCSF

GE HealthCare, UCSF, Cancer Imaging, Neurodegenerative Disease Imaging, Precision Oncology, Brain Health, Joint Research Program, Care Innovation Hub

GE HealthCare and UCSF Launch ‘Care Innovation Hub’ to Revolutionize Medical Imaging for Cancer and Neurodegenerative Diseases

11 months ago talkbio0Tagged Automated (qualifier value), brain health, ELAVL2 gene, GE HealthCare, innovation, Magnetic Resonance Imaging, Medical Imaging, Neoplasms, Neurodegenerative Disorders, Precision - temporal, radiopharmaceutical therapies, UCSF

GE HealthCare, UCSF, Care Innovation Hub, medical imaging, cancer, neurodegenerative diseases, precision oncology, brain health, automated imaging techniques, MRI, radiopharmaceutical therapies.

Light Horse Therapeutics Secures $62M Series A Funding and Partners with Novartis for Cancer Therapies

11 months ago talkbio0Tagged Cancer Therapeutic Procedure, Funding, genetic editing, Light Horse, Novartis, Precision - temporal, Series, small molecule therapeutics

Light Horse Therapeutics, Novartis, Series A funding, cancer therapies, small molecule therapeutics, precision genetic editing platform

Light Horse Therapeutics Secures $1 Billion+ Novartis Collaboration on Launch Day

11 months ago talkbio0Tagged Drug Discovery, Genome Editing, Light Horse, Novartis, Precision - temporal, small molecule therapeutics, strategic collaboration

Light Horse Therapeutics, Novartis, biotech, strategic collaboration, small molecule therapeutics, precision genome editing, drug discovery

Breakthrough in Graft-Versus-Host Disease Treatment: MaaT013 Microbiome Therapy Shows Unprecedented Efficacy

11 months ago talkbio0Tagged acute, Fecal Microbiota Transplantation, Graft-Versus-Host Disease, GvHD, MaaT013, Microbiome Therapy, Precision - temporal, Science of nutrition, Steroid-Resistant

Graft-Versus-Host Disease (GvHD), Microbiome Therapy, MaaT013, Acute GvHD, Steroid-Resistant GvHD, Faecal Microbiota Transplantation, Precision Nutrition

FDA Approves Illumina’s TruSight Oncology Comprehensive Test for Pan-Cancer Companion Diagnostics

1 year ago talkbio0Tagged Approved, cellular targeting, Comprehensive, Diagnostics, Gene Fusion, Illumina, Neoplasms, NTRK, pan-cancer, Pet Animal, Precision - temporal, RET protein, human, TruSight Oncology, United States Food and Drug Administration

FDA approval, Illumina, TruSight Oncology Comprehensive, pan-cancer, companion diagnostics, NTRK gene fusions, RET fusion-positive NSCLC, targeted therapies, precision oncology.